

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**CLARIFICATION IN RELATION TO
THE CIRCULAR, NOTICE AND PROXY FORM FOR,
AND
POLL RESULTS OF, THE 2025 FIRST EXTRAORDINARY GENERAL
MEETING HELD ON 5 SEPTEMBER 2025**

References are made to (i) the circular of Sunshine Lake Pharma Co., Ltd. (the “**Company**”) dated 19 August 2025 (the “**Circular**”); (ii) the notice of the 2025 first extraordinary general meeting of the Company (the “**EGM**”) dated 19 August 2025 (the “**Notice**”); and (iii) the proxy form of the Company for use at the EGM (the “**Proxy Form**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Circular, Notice and Proxy Form.

**CLARIFICATION IN RELATION TO THE CIRCULAR, NOTICE AND PROXY
FORM**

The Company would like to clarify that the Company does not intend to obtain a repurchase mandate from the Shareholders as at the date of this announcement and therefore any reference in the Circular, Notice and Proxy Form to “allot, issue or dispose of additional Shares and/or to sell Treasury Shares of the Company” shall be amended as “allot, issue or **deal (dealt) with disposal** of additional Shares ~~and/or to sell Treasury Shares of the Company~~” and any other reference to the “selling of Treasury Shares” pursuant to the General Issue Mandate shall be deleted accordingly.

The above information is supplemental to and should be read in conjunction with the Circular, Notice and Proxy Form. Save as disclosed above, all the other information contained in the Circular, Notice and Proxy Form remain unchanged. The above information does not affect the validity of the Proxy Form, and all submitted Proxy Forms remained effective.

POLL RESULTS OF THE EGM

The EGM has been held on Friday, 5 September 2025 at Conference Room, 3/F, Sales Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the PRC. The EGM was duly and validly convened in accordance with the Company Law and other relevant laws and regulations of the PRC, the Listing Rules and the Articles of Association.

On the date of the EGM, the total number of shares issued by the Company was 576,656,047 shares, comprising a total of 463,943,215 Domestic Shares and a total of 112,712,832 H Shares issued, all of which conferred upon their holders the right to attend the EGM and to vote for, against or abstain from voting on the resolution proposed at the EGM. Shareholders (either in person or by proxy) present at the EGM held 433,613,495 Shares carrying voting rights, representing approximately 75.19% of the total number of issued Shares carrying voting rights.

No shareholder was required under the Listing Rules to abstain from voting on the resolution proposed at the EGM. There were no Shares entitling the holder to attend and abstain from voting in favour of the proposed resolution at the EGM pursuant to Rule 13.40 of the Listing Rules. No shareholder has indicated in the EGM Circular that they intend to vote against or abstain from voting on the proposed resolution.

The proposed resolution was voted on by poll. The Company's H-share share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the counting of votes at the EGM. Two shareholder representatives and one supervisor of the Company also acted as scrutineers for the vote-taking and counting.

All Directors have attended the EGM.

POLL RESULTS OF THE EGM

The poll results of the EGM are as follows:

Special Resolution		Number of votes and percentage of total votes (%)		
		For	Against	Abstain
1	To consider and approve the grant of a general mandate to the Board to allot, issue and deal with additional Shares of the Company during the Relevant Period in an amount not exceeding 20% of the total number of issued Shares of the Company (excluding Treasury Shares) on the date of passing of this resolution, and to authorise the Board to (1) make corresponding amendments to the Articles of Association of the Company as appropriate to reflect the new share capital structure after the allotment or issue of Shares; and (2) formulate and implement any specific share issue schemes pursuant to any exercise of the general mandate.	429,799,403 (99.120394%)	3,814,092 (0.879606%)	0 (0.000000%)

As the above resolution was voted in favour of by more than two-thirds of the votes cast by shareholders (including their proxies) attending the EGM, such resolution was duly passed as a special resolution.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
5 September, 2025

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.